Arvinas, INC 10-Q quarterly reports

Arvinas announces Q1 2026 financial results, highlighting significant revenue decrease offset by progress in clinical pipeline and the landmark FDA approval of VEPPANU.

Arvinas, Inc. reported a significant reduction in net loss for the nine months ended September 30, 2025, driven by collaboration revenue and cost-saving measures, while advancing its PROTAC degrader pipeline and announcing a strategic shift for vepdegestrant commercialization.

Arvinas, Inc. reports mixed Q2 2025 results with a significant revenue increase driven by accounting estimates, a net income, and a workforce reduction, while advancing its PROTAC pipeline.

Arvinas reports a strong first quarter in 2025, marked by significant revenue growth from collaborations and continued advancement of its clinical programs, particularly vepdegestrant.

Arvinas reported its third quarter 2024 financial results, highlighting a significant increase in revenue due to a new licensing agreement, while also detailing progress in its clinical programs.

Arvinas, a clinical-stage biotechnology company, announced its second quarter 2024 financial results, marked by a significant collaboration with Novartis and continued progress in its clinical programs.

Arvinas, a clinical-stage biotechnology company, announced its first quarter 2024 financial results, alongside a significant strategic collaboration with Novartis for its ARV-766 program.